Home Technology Solutions ACO/Clinical Studies

Accountable Care Organizations/Clinical Studies

Williams Bros. LTC can help with 22 out of 33 ACO Quality Measures

Consultant Pharmacist CHF Study     Full Study Results Poster

Inhibitors of Renin-Angiotensin System and Consultant Pharmacist Intervention

Inhibitors of Renin-Angiotensin System Therapy Results

  • ACEI/ARB Therapy was administered to 50.70% to 56.07% of residents with a diagnosis of Health Failure

  • Initially an increase utilization of therapy was noted but ultimately reduction in therapy occurred

    • 52.43% to 56.07% (6.94% Improvement) from June 2013 to December 2013

    • 52.43% to 50.70% (3.30% Reduction) from June 2013 to September 2014

  • Simultaneously an increase in ACEI/ARB Therapy Intolerance is noted

    • 3.78% to 6.57% (73.81% Increase)

    • Reaching 9.39% (148.4% Increase)

Inhibitors of Renin-Angiotensin System Therapy Influenced by Consultant Pharmacist

  • Recommendation data tallied for these six specific months

    • 41 recommendations with prescriber response

    • 30 positive prescriber responses

    • 73% approval of recommendation

Beta Adrenergic Blockers and Consultant Pharmacist Intervention

Total Beta Adrenergic Blocker Therapy Improvements

  • Total Beta Adrenergic Blocker Therapy administration increased from 56.49% to 62.68% (10.96% Improvement)

  • Non-Preferred Beta Adrenergic Blocker Thrapy reduced from 24.86% to 15.26% (38.6


Beta Adrenergic Blocker Therapy Improvements Influenced by Consultant Pharmacist

  • Recommendation data tallied for these six specific months

    • 32 recommendations with prescriber response

    • 29 positive prescriber responses

    • 91% approval of recommendations

Calcium Channel Blockers and Consultant Pharmacist Intervention

Calcium Channel Blocker Therapy Reductions

  • Total Calcium Channel Blocker Therapy administration reduced from 19.19% to 14.55% (24.18% Reduction)

  • Calcium Channel Blocker Therapy with Negative Inotropic effects reduced from 8.11% to 5.87% (27.62%)

Calcium Channel Blocker Therapy Reductions Influenced by Consultant Pharmacist

  • Recommendation data tallied for these six specific months

    • 25 recommendations with prescriber response

    • 19 positive prescriber responses

    • 76% approval of recommendations